MeSH tree: C10.114.375.500.200
A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows disability progression in people ...
May 28, 2026
0
6
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a form of MS thought to ...
Apr 15, 2026
0
11
A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.
Jan 2, 2026
0
74
Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn result in vision impairments, ...
The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new research led by Oregon ...
Dec 15, 2025
0
21
About 100,000 of the estimated million people in the United States with multiple sclerosis (MS) have a progressive form of the disease, with symptoms that worsen continuously or after periods of remission.
Oct 14, 2025
0
12
Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), likely contributing to the persistent inflammation characteristic of the disease.
Oct 10, 2025
0
67
A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central nervous system. The findings suggest that neural stem cell‐based therapies hold promise as a potential ...
Jul 7, 2025
0
29
New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in people with non-relapsing ...
Apr 9, 2025
0
25
A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay ...
Apr 8, 2025
0
34
